A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (Vidaza(R)) in Adult Japanese Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)

Trial Profile

A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (Vidaza(R)) in Adult Japanese Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs Panobinostat (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 05 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 07 Apr 2014 Planned End Date changed from 1 Jan 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 07 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top